Pulmonary Hypertension

Sotatercept Improves Small Airway Disease and Hyperinflation in Patients With PH

European Respiratory Journal, 2026Research letterSource: Abstract not available — Letter formatDOI: 10.1183/13993003.02731-2025PMID 41856569

Authors: Mount Sinai PH group
Journal / date: European Respiratory Journal, 2026
DOI / URL: 10.1183/13993003.02731-2025 | PMID 41856569
Source basis: Abstract not available — Letter format
Study type: Research letter
PH group: Mixed (PAH cohort, likely with small-airway comorbidity)
Key finding (inferred from title): Sotatercept reduced small airway disease and hyperinflation in PH patients — a previously unreported pulmonary effect beyond pulmonary vascular remodeling.
Why it matters (clinical takeaway):

Suggests sotatercept may have favorable effects on the lung parenchyma/airways in addition to its established PVR-lowering effect — relevant when considering its use in patients with overlapping airway disease.
Letter format and limited public detail — interpret as hypothesis-generating until full data are available.

Caveats / limitations: Abstract not available via PubMed; details require full-text access. Likely small N and exploratory.
Referenced trials pulled forward: STELLAR (sotatercept PAH) — to add on next pass.